Interesting data suggesting the Pfizer/BioNTech works best as a three-dose vaccine. Initial 3-dose antibody titres being so much higher than 2-dose ones makes a stronger case than I had anticipated for administrating boosters outside just the most at-risk demographies.
Interesting data suggesting the Pfizer/BioNTech works best as a three-dose vaccine. Initial 3-dose antibody titres being so much higher than 2-dose ones makes a stronger case than I had anticipated for administrating boosters outside just the most at-risk demographies.
@BallouxFrancois One month follow up is bogus. Get back to us after a year.
@santa_care Antibody titre waning follows largely parallel curves irrespective of the point they start from. If they start from higher up they take longer to reach the point where they are too low to protect against infection.